CDER Features Valsartan in Report on Drug Safety Priorities for 2018

Drug Industry Daily
A A
CDER released its latest annual report on drug safety priorities on Tuesday, detailing how it approached drug safety in 2018 — including how it handled the valsartan impurity crisis.

To View This Article:

Login

Subscribe To Drug Industry Daily